Advertisement

Antirheumatika und Antiphlogistika

  • Rainer H. Böger
  • Gerhard Schmidt

Zusammenfassung

Der größte Teil der Verordnungen der Antirheumatika und Antiphlogistika entfallt auf nichtsteroidale Antiphlogistika (79%) und Rheumasalben (13%). Zahlenmäßig klein, aber von wachsender medizinischer Bedeutung sind die remissionsinduzierenden Antirheumatika (5%). In der Gruppe der nichtsteroidalen Antiphlogistika dominiert Diclofenac. Aber auch die Cydooxygenase-2-lnhibitoren gewinnen weiterhin mengenmäßig an Bedeutung. Die relativ häufig verwendeten Rheumasalben sind möglicherweise aufgrund der wiederholten kritischen Bewertungen 2003 weiter zurückqegangen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arzneimittelkommission der deutschen Ärzteschaft (1997): Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen. Arzneiverordnung in der Praxis. Sonderheft 5, 8.Google Scholar
  2. Bauer HW, Klasser M, von Hanstein KL, Rolinger H, Schladitz G et al. (1999): Oxaceprol is as effective as diclofenac in the therapy of Osteoarthritis of the knee and hip. Clin Rheumatol 18: 4–9.PubMedCrossRefGoogle Scholar
  3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528.PubMedCrossRefGoogle Scholar
  4. Brater DC, Harris C, Redfern JS, Gertz BJ (2001): Renal effects of COX-2 selective inhibitors. Am J Nephrol 21:1–15.PubMedCrossRefGoogle Scholar
  5. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D et al. (2001): Classic NSAID and selective cyclooxygenase (COX)-l and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 53:343–353.PubMedCrossRefGoogle Scholar
  6. Bundesgesundheitsamt (1987): Monographie der Kommission E über Brennesselkrautextrakt. Bundesanzeiger Nr. 76 vom 23. April 1987.Google Scholar
  7. Burnham R, Gregg R, Healy P, Steadward R (1998): The effectiveness of topical diclofenac for lateral epicondylitis. Clin J Sport Med 8: 78–81.PubMedCrossRefGoogle Scholar
  8. Castell JV, Friedrich G, Kuhn CS, Poppe GE (1997): Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 273:G139–G146.PubMedGoogle Scholar
  9. Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 869.PubMedCrossRefGoogle Scholar
  10. Chrubasik S, Junck H, Bretschwerdt H, Conradt C, Zappe H (1999): Effectiveness of Harpagophytum extract WS 1531 in the treatment of exacerbation of low back pain: a randomized, placebo-controlled, double-blind study. Eur J Anaesthesiol 16:118–129.PubMedGoogle Scholar
  11. Cipollone F, Rocca B, Patrono C (2004): Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler. Thromb Vase Biol 24: 246–255.CrossRefGoogle Scholar
  12. Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413–421.PubMedCrossRefGoogle Scholar
  13. Dequeker J, Hawkey C, Kahan A et al. (1998): Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficaey large-scale evaluation of COX-inhibiting therapies (SELECT) trial in Osteoarthritis. Br J Rheumatol 37: 946–951.PubMedCrossRefGoogle Scholar
  14. Dickson DJ (1991): A double-blind evaluation of topical piroxicam gel with oral Ibuprofen in Osteoarthritis of the knee. Curr Ther Res 49:199–207.Google Scholar
  15. Diebschlag W (1986): Diclofenac bei stumpf-traumatischen Sprunggelenkschwellungen. Fortschr Med 104:437–440.PubMedGoogle Scholar
  16. Drovanti A, Bignamini AA, Rovati AL (1980): Therapeutic activity of oral glucosamine sulfate in osteoarthrosis: a placebo-controlled double-blind investigation. Clin Ther 3: 260–272.PubMedGoogle Scholar
  17. Eccles M, Freemantle N, Mason J (1998): North of England evidence based guideline development project: summary guideline for non steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. Brit Med J 317: 526–530.PubMedCrossRefGoogle Scholar
  18. El Hadidi T, El Garf A (1991): Double-blind study comparing the use of Voltaren Emulgel versus regular gel during ultrasonic sessions in the treatment of localized traumatic and rheumatic painful conditions. J Int Med Res 19: 219–227.PubMedGoogle Scholar
  19. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al. (1999): Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double blind comparison. Lancet 354: 2106–2111.PubMedCrossRefGoogle Scholar
  20. Eras J, Perazella MA (2001): NSAIDs and the kidney revistied: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 321:181–190.PubMedCrossRefGoogle Scholar
  21. Evans JMM, MacDonald TM (1996): Tolerability of topical NSAIDs in the elderly. Drugs Aging 9:101–108.PubMedCrossRefGoogle Scholar
  22. Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppression of Prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265:16737–16740.PubMedGoogle Scholar
  23. Göbel H, Heinze A, Ingwersen M, Niederberger U, Gerber D (2001): Harpagophytum-Extrakt LI 174 (Teufelskralle) bei der Behandlung spezifischer Rückenschmerzen. Schmerz 15:10–18.PubMedCrossRefGoogle Scholar
  24. Gondolph-Zink B, Gronwald U (1996): Wirkstoffkonzentrationen in artikularen und periartikulären Geweben des Kniegelenkes nach kutaner Anwendung von Diclofenac-Diethylammonium Emulgel. Akt Rheumatol 21: 298–304.CrossRefGoogle Scholar
  25. Gøtzsche PC (2000): Extracts from „Clinical evidence“ non steroidal anti-inflammatory drugs. Brit Med J 320:1058–1061.PubMedCrossRefGoogle Scholar
  26. Grace D, Rogers J, Skeith K, Anderson K (1999): Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with Osteoarthritis of the knee. J Rheumatol 26:2659–2663.PubMedGoogle Scholar
  27. Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM (1998): Selective cyclo-oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Brit J Pharmacol 123: 927–935.CrossRefGoogle Scholar
  28. Hawkey CJ (1999): COX-2 inhibitors. Lancet 353:307–314.PubMedCrossRefGoogle Scholar
  29. Hawkey C, Kahan A, Steinbrück K, Alegre C, Baumelou E et al. (1998): Gastrointestinal tolerability of meloxicam compared to diclofenac in Osteoarthritis patients. Br J Rheumatol 37: 937–945.PubMedCrossRefGoogle Scholar
  30. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E et al. (2000): Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with Osteoarthritis. Arthritis Rheum 43: 370–377.PubMedCrossRefGoogle Scholar
  31. Hosie GAC (1993): The topical NSAID, felbinac, versus oral ibuprofen: a comparison of efficacy in the treatment of acute lower back injury. Br J Clin Res 4: 5–17.Google Scholar
  32. Hotz G, Frank T, Zoller J, Wiebelt H (1989): Antiphlogistic effect of bromelaine following third molar removal. Dtsch Zahnärztl Z 44: 830–832.PubMedGoogle Scholar
  33. Juni P, Rutjes AWS, Dieppe PA (2002): Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Brit Med J 324: 1287–1288.PubMedCrossRefGoogle Scholar
  34. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al. (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with Osteoarthritis. Gastroenterology 117: 776–783.PubMedCrossRefGoogle Scholar
  35. Langman MJS, Weil J, Wainwright P, Lawson DH, Rawlins MD et al. (1994): Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323:1075–1052.CrossRefGoogle Scholar
  36. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al. (1999): Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 282:1929–1933.PubMedCrossRefGoogle Scholar
  37. Masson M (1995): Bromelain in blunt injuries of the locomotor System. A study of observed applications in general practice. Fortschr Med 113: 303–306.PubMedGoogle Scholar
  38. McAlindon TE, LaValley MP, Gulin JP, Felson DT (2000): Glucosamine and chondroitin for treatment of Osteoarthritis. A systematic quality assessment and metaanalysis. JAMA 283:1469–1475.PubMedCrossRefGoogle Scholar
  39. Menninger H (1998): Basistherapeutische Kombinationstherapie bei chronischer Polyarthritis: Ein Überblick. Z Rheumatol 57: 25–30.PubMedCrossRefGoogle Scholar
  40. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sei USA 90:11693–11697.CrossRefGoogle Scholar
  41. Moore RA, Tramer MR, Caroll D, Wiffen PJ, McQuay HJ (1998): Quantitative systematic review of topically applied non-steroidal anti-inflammatory drugs. Brit Med J 316: 333–338.PubMedCrossRefGoogle Scholar
  42. Müller M, Mascher H, Kikuta C, Schäfer S, Brunner M et al. (1997): Diclofenac concentrations in defined tissue layers after topical administration. Clin Pharmacol Ther 62:293–299.PubMedCrossRefGoogle Scholar
  43. Mukherjee D, Nissen SE, Topol EJ (2001): Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–959.PubMedCrossRefGoogle Scholar
  44. Newberry R, Shuttleworth P, Rapier C (1992): A multicentre postmarketing surveillance study to evaluate the safety and efficacy of felbinac 3% gel in the treatment of musculoskeletal disorders in general practice. Eur J Clin Res 3:139–150.Google Scholar
  45. Nocker W, Diebschlag W (1991).: Behandlung akuter Sprunggelenkdistorsionen. Z Allg Med 67: 560–564.Google Scholar
  46. Obertreis B, Giller K, Teucher T, Behnke B, Schmitz H (1996): Antiphlogistische Effekte von Extractum Urticae dioieae foliorum im Vergleich zu Kaffeoyläpfelsäure. Arzneim Forsch 46:52–56.Google Scholar
  47. O’Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W et al. (1996): Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. 334:1287–1291.CrossRefGoogle Scholar
  48. Peskar BM, Maricic N, Gretzera B, Schuligoi B, Schmassmann A (2001): Role of cyclooxygenase-2 in gastric mucosal defense. Life Sei 69:2993–3003CrossRefGoogle Scholar
  49. Pujalte JM, Llavore EP, Ylescupidez FR (1980): Double-blind clinical evaluation of oral glucosamine sulphate in the basic treatment of osteoarthrosis. Curr Med Res Op 7:110–114.CrossRefGoogle Scholar
  50. Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frölich JC (1991): Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative Joint disease. Br J Clin Pharmacol 31:537–541.PubMedCrossRefGoogle Scholar
  51. Reichelt A, Förster KK, Fischer M, Rovati LC, Setnikar I (1994): Efficaey and safety of intramuscular glucosamine sulfate in Osteoarthritis of the knee. Arzneim Forsch 44: 75–80.Google Scholar
  52. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O et al. (2001): Long-term effects of glucosamine sulphate on Osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357:251–256.PubMedCrossRefGoogle Scholar
  53. Riess W, Schmid K, Botta L, Kobayashi K, Moppert J et al. (1986): Die perkutane Resorption von Diclofenac. Arzneim Forsch 36:1092–1096.Google Scholar
  54. Rindone JP, Hiller D, Collacott E, Nordhaugen N, Arriola G (2000): Randomized, controlled trial of glucosamine for treating Osteoarthritis of the knee. West J Med 172:91–94.PubMedCrossRefGoogle Scholar
  55. Roth SH (1995): A controlled clinical investigation of 3% diclofenac/2.5% sodium hyaluronate topical gel in the treatment of uncontrolled pain in chronic oral NSAID users with Osteoarthritis. Int J Tissue React 17:129–132.PubMedGoogle Scholar
  56. Rovati LC (1992): Clinical research in Osteoarthritis: design and results of short-term and long-term trials with disease-modifying drugs. Int J Tiss Reac 14: 243–251.Google Scholar
  57. Sandholzer H, Kochen MM (1991): Perkutane Rheumatherapie. Pharma-Kritik 13: 13–16.Google Scholar
  58. Schapira D, Linn S, Scharf Y (1991): A placebo-controlled evaluation of diclofenac diethylamine salt in the treatment of lateral epicondylitis of the elbow. Curr Ther Res 49:162–168.Google Scholar
  59. Schubotz R, Hausmann L (1977): Behandlung degenerativer Gelenkerkrankungen mit N-Azetyl-hydroxyprolin. Therapiewoche 27:4248–4252.Google Scholar
  60. Setnikar I, Palumbo R, Canali S, Zanolo G (1993): Pharmacokinetics of glucosamine in man. Arzneim Forsch 43:1109–1113.Google Scholar
  61. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for Osteoarthritis and rheumatoid arthritis. JAMA 284:1247–1255.PubMedCrossRefGoogle Scholar
  62. Smolen JS, Kalden JR, Scott DJ, Rozman B, Kvien TK, Larsen A et al. for the European Leflunomide Study Group (1999): Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 353:259–266.PubMedCrossRefGoogle Scholar
  63. Towheed TE, Anastassiades TP (2000): Glucosamine and chondroitin for treating Symptoms of Osteoarthritis: evidence is widely touted but incomplete. JAMA 283:1483–1484.PubMedCrossRefGoogle Scholar
  64. Vagt CW, Kaiser T, Leineweber G (1990): Wirksamkeitsvergleich der oralen Therapie mit Oxazeprol versus Ibuprofen bei Gonarthrose und Coxarthrose. Rheuma 10: 263–267.Google Scholar
  65. Zacher J, Burger KJ, Färber L, Gräve M, Abberger H, Bertsch K (2001): Topisches Diclofenac Emulgel versus orales Ibuprofen in der Therapie der aktivierten Arthrose der Fingergelenke (Heberden-und/oder Bouchard-Arthrose). Akt Rheumatol 26:7–14.CrossRefGoogle Scholar
  66. Zeidler H (1996): Nichtsteroidale Antiphlogistika. Neue Wege zu einer rationalen, sparsamen und risikoärmeren Verordnung. Akt Rheumatol 21:269–271.CrossRefGoogle Scholar
  67. Zimmermann J, Siguencia J, Tsvang E (1995): Upper gastrointestinal hemorrhage associated with cutaneous application of diclofenac gel. Am J Gastroenterol 90: 2032–2034.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Rainer H. Böger
    • 1
  • Gerhard Schmidt
    • 2
  1. 1.Institut für Experimentelle und Klinische PharmakologieUniversitäts-Krankenhaus EppendorfHamburg
  2. 2.Institut für Pharmakologie und Toxikologie der UniversitätGöttingen

Personalised recommendations